불면증 역학 분석과 예측(2026년)

The Global Insomnia prevelance is estimated to grow from 66.4 million patients in 2026 at a CAGR of 0.8% to 71.1 million patients in 2035.

The global insomnia epidemiology landscape reflects a significant and growing public health burden, with insomnia recognized as one of the most prevalent sleep disorders worldwide. Epidemiology analysis provides comprehensive insights into disease prevalence, incidence, diagnosed patient populations, demographic trends, disease severity, risk factors, regional distribution, and future epidemiological projections. Increasing awareness of sleep health, aging populations, rising stress levels, mental health disorders, and changing lifestyles continue to contribute to the growing burden of insomnia across both developed and emerging economies.

Insomnia is characterized by persistent difficulty initiating sleep, maintaining sleep, or experiencing restorative sleep despite adequate opportunity for rest, leading to impaired daytime functioning. Recent global epidemiological evidence estimates that approximately 852 million adults worldwide are living with clinically significant insomnia, representing approximately 16.2% of the global adult population, while nearly 415 million adults experience severe insomnia. Women consistently demonstrate higher prevalence rates than men across all age groups, and disease burden increases with advancing age.

The epidemiology of insomnia is influenced by numerous biological, psychological, environmental, and socioeconomic factors. Anxiety disorders, depression, cardiovascular disease, chronic pain, neurological disorders, obesity, shift work, excessive screen exposure, and aging all contribute to increased disease prevalence. Urbanization, changing work patterns, and increasing digital device usage have further intensified sleep disturbances in many populations, creating additional healthcare challenges.

Advances in digital health technologies, sleep monitoring devices, wearable sensors, artificial intelligence-assisted diagnostics, and telemedicine are improving disease detection and patient monitoring. Greater recognition of insomnia as an independent medical condition rather than merely a symptom of other illnesses has also improved diagnosis rates and encouraged earlier clinical intervention. As healthcare systems continue prioritizing sleep medicine and preventive healthcare, the diagnosed patient population is expected to expand steadily throughout the forecast period.

Market Drivers

Rising Global Burden of Sleep Disorders

• Increasing stress, mental health disorders, aging populations, and lifestyle changes continue contributing to higher insomnia prevalence worldwide.
• Growing public awareness of sleep health is encouraging earlier diagnosis and treatment.

Increasing Mental Health Awareness

• Depression, anxiety disorders, and chronic psychological stress remain among the strongest contributors to insomnia.
• Expanding mental health services are improving identification and management of sleep disorders.

Aging Population

• Older adults experience higher rates of insomnia due to age-related physiological changes, chronic illnesses, and multiple comorbidities.
• Global population aging is expected to increase the overall patient population during the forecast period.

Expansion of Sleep Medicine Services

• Healthcare systems continue investing in sleep clinics, specialized diagnostic centers, telemedicine platforms, and multidisciplinary sleep management programs.
• Improved access to specialist care is strengthening diagnosis rates.

Advances in Diagnostic Technologies

• Wearable sleep monitors, digital sleep diaries, home sleep assessment tools, artificial intelligence, and remote patient monitoring technologies are improving disease identification and long-term epidemiological tracking.

Market Restraints

Underdiagnosis

• A significant proportion of individuals with chronic insomnia remain undiagnosed because symptoms are frequently underestimated or self-managed without professional medical evaluation.
• Limited awareness continues delaying appropriate treatment.

Limited Access to Sleep Specialists

• Many developing countries continue facing shortages of sleep medicine specialists, diagnostic laboratories, and dedicated sleep centers.
• Healthcare disparities restrict timely diagnosis and treatment.

Variability in Diagnostic Criteria

• Differences in clinical definitions, diagnostic methodologies, and epidemiological study designs may create variability in prevalence estimates across countries and regions.
• Standardization remains an ongoing challenge for epidemiological research.

Epidemiology Insights

By Disease Severity

• The patient population includes individuals with transient insomnia, short-term insomnia, chronic insomnia disorder, and severe insomnia requiring long-term medical management.
• Chronic insomnia represents the greatest clinical and economic burden because of its association with multiple comorbid conditions.

By Age Group

• Insomnia affects adults of all ages but is most frequently diagnosed among middle-aged and older adults.
• Prevalence generally increases with age because of physiological sleep changes, chronic diseases, medication use, and psychiatric comorbidities.

By Gender

• Women experience insomnia more frequently than men due to hormonal changes, pregnancy, menopause, and a higher prevalence of anxiety and depression.
• Recent epidemiological studies consistently report higher insomnia prevalence among females across virtually all adult age groups.

By Diagnosis Status

• The epidemiological population includes diagnosed patients receiving pharmacological or behavioral treatment, newly diagnosed individuals, and a substantial proportion of undiagnosed or untreated patients who continue experiencing chronic sleep disturbances.

Regional Insights

• North America represents one of the largest diagnosed insomnia populations owing to high disease awareness, advanced healthcare infrastructure, widespread access to sleep medicine specialists, and extensive use of digital health technologies. Strong public awareness and routine clinical screening continue supporting higher diagnosis rates.
• Europe maintains a significant insomnia patient population supported by comprehensive healthcare systems, specialized sleep medicine centers, and increasing investment in preventive healthcare. Germany, the United Kingdom, France, Italy, and Spain continue reporting substantial disease burden while expanding access to behavioral sleep therapies and digital health services.
• Asia Pacific is expected to witness the fastest growth in diagnosed insomnia cases during the forecast period due to rapid urbanization, increasing occupational stress, aging populations, expanding healthcare infrastructure, and improving awareness across China, Japan, India, South Korea, and Australia.
• Latin America and the Middle East & Africa are gradually improving insomnia diagnosis through healthcare modernization, expanded sleep medicine services, increased public awareness, and improved access to mental health care.

Competitive and Strategic Outlook

• The growing epidemiological burden of insomnia continues creating significant opportunities for pharmaceutical companies, healthcare providers, sleep diagnostic companies, digital health developers, and medical device manufacturers. Organizations are increasingly investing in improved screening programs, digital diagnostics, wearable sleep technologies, remote patient monitoring, and personalized sleep medicine to better identify and manage affected individuals.
• Strategic collaboration between healthcare providers, academic institutions, sleep research organizations, pharmaceutical companies, and digital health developers continues strengthening epidemiological surveillance while supporting improved patient outcomes. Future healthcare strategies are expected to emphasize early diagnosis, preventive care, precision medicine, and integration of digital sleep technologies into routine clinical practice.

Conclusion

• The global epidemiological burden of insomnia is expected to increase steadily throughout the forecast period as aging populations, mental health disorders, changing lifestyles, and chronic disease prevalence continue expanding the at-risk population. Recent evidence indicates that more than 852 million adults worldwide are affected by clinically significant insomnia, highlighting its substantial impact on public health. Continued improvements in disease awareness, diagnostic technologies, healthcare accessibility, and sleep medicine services are expected to enhance diagnosis rates and support more effective long-term disease management. Despite ongoing challenges related to underdiagnosis, healthcare disparities, and variability in diagnostic practices, continued investment in sleep health and epidemiological research is expected to strengthen patient care and healthcare planning worldwide.

Key Benefits of this Report

• Insightful Analysis: Comprehensive evaluation of global insomnia prevalence, incidence, diagnosed patient population, demographic trends, and disease burden.
• Epidemiological Assessment: Analyze patient distribution by age, gender, disease severity, diagnosis status, and geographic region.
• Market Drivers and Future Trends: Understand epidemiological developments, healthcare access improvements, and future patient population growth.
• Actionable Recommendations: Support healthcare planning, market forecasting, clinical development, and commercial strategy.
• Caters to a Wide Audience: Suitable for pharmaceutical companies, biotechnology firms, healthcare providers, investors, consultants, research organizations, public health agencies, and policymakers.

What Businesses Use Our Reports For

• Epidemiology assessment, patient population forecasting, commercial opportunity evaluation, clinical trial planning, healthcare resource allocation, market entry strategy, investment analysis, public health planning, and competitive intelligence.

Report Coverage

• Historical analysis from 2021 to 2024, Base year 2025, and Forecast period from 2026 to 2035
• Epidemiological analysis by prevalence, incidence, diagnosed cases, disease severity, age group, gender, and region
• Assessment of risk factors, disease burden, diagnosis patterns, healthcare access, and future epidemiological trends
• Analysis of unmet clinical needs, healthcare infrastructure, and patient management trends
• Regional analysis across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Overview
  • 1.1.1 Study Objectives
  • 1.1.2 Scope of Analysis
  • 1.1.3 Key Epidemiological Findings
• 1.2 Epidemiology Snapshot
  • 1.2.1 Global Prevalence Overview
  • 1.2.2 Global Incidence Overview
  • 1.2.3 Diagnosed Population Overview
  • 1.2.4 Treated Population Overview
• 1.3 Forecast Highlights (2026-2035)
  • 1.3.1 Patient Population Growth Trends
  • 1.3.2 Diagnosis Trends
  • 1.3.3 Treatment Access Trends

2. Disease Overview and Clinical Background

• 2.1 Insomnia Overview
  • 2.1.1 Definition and Classification
  • 2.1.2 Acute Insomnia
  • 2.1.3 Chronic Insomnia
  • 2.1.4 Comorbid Insomnia
• 2.2 Disease Pathophysiology
  • 2.2.1 Neurobiological Mechanisms
  • 2.2.2 Sleep-Wake Regulation Dysfunction
  • 2.2.3 Risk Factors
• 2.3 Disease Burden Assessment
  • 2.3.1 Individual Health Burden
  • 2.3.2 Mental Health Impact
  • 2.3.3 Productivity Loss
  • 2.3.4 Healthcare Resource Utilization

3. Epidemiology Methodology and Data Framework

• 3.1 Data Collection Methodology
  • 3.1.1 Population-Based Studies
  • 3.1.2 Government Health Databases
  • 3.1.3 Academic Literature Sources
  • 3.1.4 Registry and Survey Data
• 3.2 Epidemiological Definitions
  • 3.2.1 Total Population
  • 3.2.2 Prevalent Cases
  • 3.2.3 Incident Cases
  • 3.2.4 Diagnosed Cases
  • 3.2.5 Treated Cases
• 3.3 Forecast Methodology
  • 3.3.1 Baseline Population Modeling
  • 3.3.2 Forecast Assumptions
  • 3.3.3 Sensitivity Analysis

4. Global Insomnia Epidemiology Analysis

• 4.1 Total Patient Population
  • 4.1.1 Historical Trends
  • 4.1.2 Current Epidemiological Burden
  • 4.1.3 Future Population Trends
• 4.2 Prevalence Analysis
  • 4.2.1 Global Prevalence
  • 4.2.2 Age-Specific Prevalence
  • 4.2.3 Gender-Specific Prevalence
  • 4.2.4 Regional Variability
• 4.3 Incidence Analysis
  • 4.3.1 Global Incidence
  • 4.3.2 Annual New Cases
  • 4.3.3 Age-Specific Incidence
  • 4.3.4 Gender-Specific Incidence

5. Diagnosed Patient Population Analysis

• 5.1 Diagnosed Cases Assessment
  • 5.1.1 Global Diagnosed Population
  • 5.1.2 Regional Diagnosis Rates
  • 5.1.3 Historical Diagnosis Trends
• 5.2 Diagnostic Pathway Evaluation
  • 5.2.1 Patient Presentation Patterns
  • 5.2.2 Primary Care Diagnosis
  • 5.2.3 Specialist Diagnosis
  • 5.2.4 Diagnostic Delays
• 5.3 Undiagnosed Population Assessment
  • 5.3.1 Estimated Undiagnosed Population
  • 5.3.2 Barriers to Diagnosis
  • 5.3.3 Awareness Gaps

6. Treated Patient Population Analysis

• 6.1 Treatment-Seeking Population
  • 6.1.1 Healthcare Utilization Rates
  • 6.1.2 Physician Consultation Trends
  • 6.1.3 Treatment Initiation Rates
• 6.2 Treated Population Assessment
  • 6.2.1 Pharmacological Treatment Population
  • 6.2.2 Non-Pharmacological Treatment Population
  • 6.2.3 Combined Treatment Population
• 6.3 Untreated Population Assessment
  • 6.3.1 Treatment Gaps
  • 6.3.2 Access Barriers
  • 6.3.3 Economic Constraints

7. Demographic and Clinical Segmentation

• 7.1 Age-Based Analysis
  • 7.1.1 Pediatric Population
  • 7.1.2 Adolescent Population
  • 7.1.3 Adult Population
  • 7.1.4 Elderly Population
• 7.2 Gender-Based Analysis
  • 7.2.1 Female Patient Population
  • 7.2.2 Male Patient Population
  • 7.2.3 Gender-Related Disease Trends
• 7.3 Severity-Based Analysis
  • 7.3.1 Mild Insomnia
  • 7.3.2 Moderate Insomnia
  • 7.3.3 Severe Insomnia
• 7.4 Comorbidity-Based Analysis
  • 7.4.1 Psychiatric Comorbidities
  • 7.4.2 Cardiovascular Comorbidities
  • 7.4.3 Neurological Comorbidities
  • 7.4.4 Metabolic Comorbidities

8. Epidemiological Forecast Analysis (2026-2035)

• 8.1 Global Forecast
  • 8.1.1 Prevalence Forecast
  • 8.1.2 Incidence Forecast
  • 8.1.3 Diagnosed Population Forecast
  • 8.1.4 Treated Population Forecast
• 8.2 Forecast Drivers
  • 8.2.1 Population Aging
  • 8.2.2 Urbanization Trends
  • 8.2.3 Mental Health Burden
  • 8.2.4 Lifestyle Changes
• 8.3 Forecast Constraints
  • 8.3.1 Underdiagnosis
  • 8.3.2 Healthcare Access Limitations
  • 8.3.3 Awareness Deficits

9. Healthcare Access and Patient Journey Analysis

• 9.1 Patient Journey Assessment
  • 9.1.1 Symptom Recognition
  • 9.1.2 Healthcare Engagement
  • 9.1.3 Diagnosis
  • 9.1.4 Treatment Initiation
• 9.2 Healthcare Access Analysis
  • 9.2.1 Primary Care Access
  • 9.2.2 Sleep Specialist Availability
  • 9.2.3 Digital Health Utilization
• 9.3 Treatment Access Assessment
  • 9.3.1 Geographic Access Differences
  • 9.3.2 Socioeconomic Access Differences
  • 9.3.3 Insurance Coverage Impact

10. Geographic Analysis

• 10.1 North America
  • 10.1.1 Prevalence Trends
  • 10.1.2 Incidence Trends
  • 10.1.3 Diagnosis Trends
  • 10.1.4 Treatment Access
• 10.2 Europe
  • 10.2.1 Prevalence Trends
  • 10.2.2 Incidence Trends
  • 10.2.3 Diagnosis Trends
  • 10.2.4 Treatment Access
• 10.3 Asia-Pacific
  • 10.3.1 Prevalence Trends
  • 10.3.2 Incidence Trends
  • 10.3.3 Diagnosis Trends
  • 10.3.4 Treatment Access
• 10.4 Latin America
  • 10.4.1 Prevalence Trends
  • 10.4.2 Incidence Trends
  • 10.4.3 Diagnosis Trends
  • 10.4.4 Treatment Access
• 10.5 Middle East & Africa
  • 10.5.1 Prevalence Trends
  • 10.5.2 Incidence Trends
  • 10.5.3 Diagnosis Trends
  • 10.5.4 Treatment Access

11. Key Countries Analysis

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 China
• 11.9 Japan
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

12. Public Health and Economic Burden Analysis

• 12.1 Healthcare Resource Utilization
  • 12.1.1 Outpatient Visits
  • 12.1.2 Sleep Clinic Utilization
  • 12.1.3 Hospital Resource Impact
• 12.2 Economic Burden Assessment
  • 12.2.1 Direct Medical Costs
  • 12.2.2 Indirect Productivity Costs
  • 12.2.3 Employer Burden
• 12.3 Public Health Initiatives
  • 12.3.1 Awareness Programs
  • 12.3.2 Sleep Health Campaigns
  • 12.3.3 Access Improvement Initiatives

13. Future Outlook and Strategic Insights

• 13.1 Epidemiological Outlook
  • 13.1.1 Long-Term Prevalence Trends
  • 13.1.2 Long-Term Incidence Trends
  • 13.1.3 Diagnosis Rate Evolution
• 13.2 Healthcare System Outlook
  • 13.2.1 Expansion of Sleep Medicine Services
  • 13.2.2 Telehealth Adoption
  • 13.2.3 Digital Sleep Health Monitoring
• 13.3 Strategic Insights
  • 13.3.1 High-Burden Populations
  • 13.3.2 Underserved Regions
  • 13.3.3 Priority Healthcare Interventions

14. Methodology and Data Framework

• 14.1 Data Sources
  • 14.1.1 Government Agencies
  • 14.1.2 Academic Publications
  • 14.1.3 International Health Organizations
  • 14.1.4 National Health Surveys
• 14.2 Forecasting Methodology
  • 14.2.1 Population Modeling
  • 14.2.2 Epidemiological Modeling
  • 14.2.3 Validation Procedures
• 14.3 Data Validation
  • 14.3.1 Data Verification
  • 14.3.2 Cross-Source Validation
  • 14.3.3 Limitations